

CITATION REPORT

List of articles citing

Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis

DOI: 10.1002/art.30195

Arthritis and Rheumatism, 2011, 63, 775-82.

Source: <https://exaly.com/paper-pdf/51521446/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
79	Contemporary management of Raynaud's phenomenon and digital ischaemic complications. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 555-61	5.3	43
78	Current world literature. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 620-5	5.3	
77	In Brief. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 195-195	8.1	
76	Cardiac uses of phosphodiesterase-5 inhibitors. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 9-15	15.1	65
75	The pathogenesis, diagnosis and treatment of Raynaud phenomenon. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 469-79	8.1	176
74	Les inhibiteurs de la phosphodiesterase 5 dans les maladies vasculaires systémiques. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012 , 79, 187-190	0.1	
73	Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 813-9	6.1	20
72	Raynaud's Phenomenon. 2012 , 313-329		3
71	Phosphodiesterase 5 inhibitors in vascular systemic disorders. <i>Joint Bone Spine</i> , 2012 , 79, 338-40	2.9	2
70	Nonarteriosclerotic vascular disease. <i>Surgical Clinics of North America</i> , 2013 , 93, 833-75, viii	4	12
69	[Hand involvement in systemic sclerosis]. <i>Presse Medicale</i> , 2013 , 42, 1616-26	2.2	10
68	Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1696-9	2.4	107
67	Complex Raynaud's phenomenon: evolving concepts of management. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 689-706	1.5	
66	Recommendations for the management and treatment of systemic sclerosis. <i>Revista Brasileira De Reumatologia</i> , 2013 , 53, 258-275		1
65	Current medical and surgical management of Raynaud's syndrome. <i>Journal of Vascular Surgery</i> , 2013 , 57, 1710-6	3.5	28
64	Recomendações sobre diagnóstico e tratamento da esclerose sistêmica. <i>Revista Brasileira De Reumatologia</i> , 2013 , 53, 258-275		5
63	Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. <i>Arthritis Care and Research</i> , 2013 , 65, 1460-71	4.7	74

62	Targeted therapies for systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 451-64	8.1	24
61	Management of Raynaud's phenomenon and digital ischemia. <i>Current Rheumatology Reports</i> , 2013 , 15, 303	4.9	38
60	Scleroderma therapy: clinical overview of current trends and future perspective. <i>Rheumatology International</i> , 2013 , 33, 1-18	3.6	12
59	Treatment options in systemic sclerosis. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 851-865	1.1	
58	Raynaud's Phenomenon. 2013 , 589-601		
57	Treatment options in Raynaud's phenomenon. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 271-282	1.1	
56	The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope. <i>American Journal of the Medical Sciences</i> , 2014 , 347, 54-63	2.2	16
55	Raynaud syndrome. <i>Techniques in Vascular and Interventional Radiology</i> , 2014 , 17, 241-6	2.6	13
54	Raynaud's phenomenon: from molecular pathogenesis to therapy. <i>Autoimmunity Reviews</i> , 2014 , 13, 655-676	6.6	85
53	Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study. <i>Rheumatology</i> , 2014 , 53, 658-64	3.9	27
52	Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors. <i>Vascular</i> , 2014 , 22, 313-6	1.3	2
51	[Pharmacology of Raynaud's phenomenon]. <i>Therapie</i> , 2014 , 69, 115-28	3.8	4
50	Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 399-417	2.4	15
49	Drug Treatment of Raynaud's Phenomenon. 2015 , 315-337		
48	Tratamiento con toxina botulínica del fenómeno de Raynaud severo. <i>Piel</i> , 2015 , 30, 410-415	0.1	2
47	Update on systemic sclerosis. <i>Current Allergy and Asthma Reports</i> , 2015 , 15, 25	5.6	8
46	Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 2015-24	3.9	81
45	Management of Raynaud's Phenomenon and Digital Ulcers. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 68-81	1.3	4

44	Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 241-8	5.3	25
43	Old medications and new targeted therapies in systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 1944-53	3.9	36
42	A Randomized Controlled Trial of Acupressure for the Treatment of Raynaud's Phenomenon: The difficulty of conducting a trial in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 226-233	2.3	3
41	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1009-15	2.4	76
40	Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 577-85	5.3	19
39	Raynaud's phenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016 , 30, 112-32	5.3	47
38	Current and future direction in the management of scleroderma. <i>Archives of Dermatological Research</i> , 2016 , 308, 461-71	3.3	3
37	The skin in autoimmune diseases-Unmet needs. <i>Autoimmunity Reviews</i> , 2016 , 15, 948-54	13.6	8
36	Raynaud phenomenon. <i>Reviews in Vascular Medicine</i> , 2016 , 4-5, 9-16		2
35	Therapeutic implications from the pathogenesis of Raynaud's phenomenon. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 723-735	5.1	8
34	Systemic sclerosis. <i>Lancet, The</i> , 2017 , 390, 1685-1699	40	764
33	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1327-1339	2.4	497
32	Points to consider-Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v45-v48	3.9	19
31	How I treat patients with systemic sclerosis in clinical practice. <i>Autoimmunity Reviews</i> , 2017 , 16, 1024-1028	13.6	16
30	Evidence-based management of Raynaud's phenomenon. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017 , 9, 317-329	3.8	15
29	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2370-2379	9.5	36
28	The safety of iloprost in systemic sclerosis in a real-life experience. <i>Clinical Rheumatology</i> , 2018 , 37, 1249-1255	10	10
27	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. <i>Journal of Dermatology</i> , 2018 , 45, 633-691	1.6	16

26	The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 431-442	5.1	6
25	Systemic sclerosis: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , 2018 , 36, 459-474	3	17
24	Use of nitroglycerin ointment to treat primary and secondary Raynaud's phenomenon: a systematic literature review. <i>Rheumatology International</i> , 2018 , 38, 2209-2216	3.6	8
23	Pharmacotherapy Options in the Management of Raynaud's Phenomenon. <i>Current Treatment Options in Rheumatology</i> , 2018 , 4, 235-254	1.3	6
22	The contemporary management of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 573-582	5.1	2
21	An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 17-27	2.3	10
20	Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019 , 46, 1326-1334	4.1	15
19	Raynaud's phenomenon.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 89-101	2.3	8
18	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. <i>Lancet Rheumatology, The</i> , 2019 , 1, e237-e246	14.2	11
17	Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity. <i>Arthritis Care and Research</i> , 2019 , 71, 1119-1126	4.7	15
16	Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13296	2.9	4
15	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 18-26	3.9	26
14	Systemic sclerosis: Update for oral health care providers. <i>Special Care in Dentistry</i> , 2020 , 40, 418-430	1.7	2
13	The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species. <i>Antioxidants</i> , 2020 , 9,	7.1	4
12	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1049-1058	9.5	19
11	Wound, pressure ulcer and burn guidelines - 4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers. <i>Journal of Dermatology</i> , 2020 , 47, 1071-1109	1.6	2
10	Design and Reporting of Randomised Controlled Trials for Raynaud's Phenomenon. 2015 , 287-297		4
9	Phosphodiesterase-5 Inhibitors in Cardioprotection. 2013 , 439-458		

8 Clinical Outcome Measures in Raynaud's Phenomenon. **2015**, 279-286

7 Secondary Raynaud's Phenomenon. **2015**, 107-127

6 Management of Digital Ischemia. **2015**, 339-360

5 Investigative Approaches to Drug Therapy. **2017**, 583-594

4 Raynaud's Phenomenon, Digital Ulcers and Nailfold Capillaroscopy. **2017**, 297-316

3 An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View. *Journal of Clinical and Aesthetic Dermatology*, **2012**, 5, 33-43 1.2 10

2 Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.. *Frontiers in Medicine*, **2021**, 8, 788250 4.9 3

1 Practical management of Raynaud's phenomenon – a primer for practicing physicians. *Current Opinion in Rheumatology*, Publish Ahead of Print, 5.3